ClinicalTrials.gg
RecruitingNCT05200260Updated Feb 10, 2025

Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

A Phase 2 interventional study of Primary debulking surgery and Neoadjuvant chemotherapy in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Carcinoma, sponsored by Shanghai Gynecologic Oncology Group. Recruiting at 9 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Shanghai Gynecologic Oncology Group · Phase 2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 395 studies in Ovarian Neoplasms with a site in China — 201 open to participants now, 233 under way, 36 of them phase 3. Ovarian Neoplasms · China.

Planned enrollment
76th of 322
220 · median 83
Started
2022
with 46 others
Phase 2
107 of 395
54 open now
Primary completion
2027-06
later than 135 of 232 live
Registered
153rd of 395
by date
Lead sponsor
9 of 395
Shanghai Gynecologic Oncology Group

Among the 395 studies in Ovarian Neoplasms with a site in China, this one is the 76th largest by planned enrollment of the 322 interventional ones that give a count, is one of 47 that started in 2022, is one of 107 in phase 2, reaches primary completion later than 135 of the 232 other live ones, and was the 153rd registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

201 of the 395 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

196 more — sign in →

All 201 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer

Read the detailed description

The purpose of this trial is to answer the fundamental question 'The Optimal Timing of Surgery' combined with Bevacizumab or Poly-adenosine Ribose Phosphate Inhbitors (PARPi), in the circumstance of primarily diagnosed advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal carcinoma.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma

Keywords

  • Ovarian Cancer
  • Primary Debulking Surgery
  • Neoadjuvant chemotherapy
  • Poly-adenosine Ribose Phosphate Inhbitors (PARPi)
  • Bevacizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females aged ≥ 18 years.
  • Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma
  • Low, Middle tumor burden and high tumor burden with cPCI score ≤ 12 based on pre-operative CT or PET/CT examination
  • Complete cytoreduction can be achieved based on CT or PET/CT examination
  • Patients must agree to undergo BRCA (breast cancer gene) and HRD (homologous recombination deficiency) testing
  • Performance status ( 0-2)
  • Adequate bone marrow, renal and hepatic function to receive chemotherapy and subsequent surgery:

    1. white blood cells >3,000/µL, ≥1,500/µL, ≥100,000/µL, ≥9 g/dL,
    2. serum creatinine \<1.25 x upper normal limit (UNL) or ≥60 mL/min according to Cockroft-Gault formula or to local lab measurement,
    3. serum \<1.25 x UNL, (SGOT) and ALT(SGPT) \<2.5 x UNL.
  • Comply with the study protocol and follow-up.
  • Patients who have given their written .

Exclusion criteria

Exclusion Criteria:

  • Non-epithelial ovarian and borderline tumors
  • Low grade ovarian cancer
  • Mucinous ovarian cancer
  • Complete cytoreduction cannot be achieved according to preoperative evaluation, including pulmonary and hepatic parenchymal , unresectable extensive pleural metastases, multiple thoracic lymph nodes metastases, brain or bone metastases
  • Patient has a known to the components of olaparib/bevacizumab or its
  • Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ, thyroid carcinoma, or breast carcinoma (without any signs of relapse or activity, early-stage).
  • Any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise adherence to the protocol.
  • Other conditions, such as religious, psychological, and other factors, that could interfere with the provision of , compliance to study procedures, or follow-up.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Upfront cytoreductive surgery with maintenance therapy

    Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy (patients with or without BRCA mutation will be maintained by PARPi or Bevacizumab respectively ).

    Procedure: Primary debulking surgery · Drug: PARP inhibitor · Drug: Bevacizumab

  • Active comparator
    Neoadjuvant chemotherapy with maintenance therapy

    Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy (patients with or without BRCA mutation will be maintained by PARPi or Bevacizumab respectively ).

    Procedure: Neoadjuvant chemotherapy · Drug: PARP inhibitor · Drug: Bevacizumab

Interventions

  • ProcedurePrimary debulking surgery

    Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.

    Also known as: PDS

  • ProcedureNeoadjuvant chemotherapy

    3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.

    Also known as: Neoadjuvant chemotherapy followed by interval debulking surgery, NACT-IDS

  • DrugPARP inhibitorsStudies of PARP inhibitorsPARP inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For patients with BRCA mutated, maintenance therapy of PARP inhibitors following CR/PR after first-line chemotherapy. In this trial, Olaparib 300mg p.o. twice daily is suggested after the front-line therapy.

    Also known as: Olaparib

  • For patients without BRCA mutated, maintenance therapy of Bevacizumab following CR/PR after first-line chemotherapy. In this trial, Bevacizumab 7.5mg per kilogram intravenous once every 3 weeks is suggested after the front-line therapy.

This study also gives OlaparibStudies of OlaparibOlaparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. 3-year overall survival

    The proportion of patients alive at 3 years after entry into the study

    Time frame: Participants will be followed for at least 3 years after randomization

Secondary outcomes

  1. Overall survival

    Time from entry into the study to any cause of death

    Time frame: Participants will be followed for at least 3 years after randomization

  2. Progression-free survival

    Time from entry into the study to the diagnosis of the first progression or recurrence or death, whichever occurs first

    Time frame: Participants will be followed for at least 3 years after randomization

  3. Post-operative complications

    The surgical complications will be evaluated at 30-day, 60-day, 90-day after upfront cytoreductive surgery or interval debulking surgery

    Time frame: Participants will be followed up to 3 months after randomization

  4. Quality of life assessments

    QLQ-C30, FACT-Q (baseline; 6 months, 12 months, 24 months and 36 months after randomization)

    Time frame: Participants will be followed for at least 3 years after randomization

  5. Accumulated treatment-free survival

    Time from the date of randomization to death from any reason, minus the total treatment time of surgery and chemotherapy after randomization (regardless of targeted therapy)

    Time frame: Participants will be followed for at least 3 years or death after randomization

  6. TFST

    Time from the date of randomization until the starting date of the first subsequent anticancer therapy or death, whichever occurred first, whichever occurred first

    Time frame: Participants will be followed for at least 3 years or death after randomization

  7. TSST

    Time from the date of randomization until the starting date of the second subsequent anticancer therapy or death, whichever occurred first

    Time frame: Participants will be followed for at least 3 years or death after randomization

  8. The pattern of the first relapse

    The number and sites of the first relapse, including pelvic, abdominal, retroperitoneal lymph nodes, distant metastases and ascites will be compared between the two groups.

    Time frame: Participants will be followed for at least 3 years or death after randomization

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jun 2027, 59 months after the start.

Of 229 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's planned 59 months is close to that.

Counting every sponsor, half of 345 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2022
First posted
Jan 20, 2022
StartActual
Jul 13, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05200260
Lead sponsor
Shanghai Gynecologic Oncology Group
Collaborators
Fudan University
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
Jul 13, 2022
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Feb 10, 2025

Study contacts

Libing Xiang
Contact
xiang.libing@zs-hospital.sh.cn
86 21 64041990 ext. 2801
Rong Jiang
Contact
jiang.rong@zs-hospital.sh.cn
86 21 64041990 ext. 2801
Libing Xiang
study chair · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion